ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer
In a small phase 2 study presented at the virtual [...]
ASCO GU 2021: Cabozantinib for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer
The past couple of years has seen a number of [...]
Cabozantinib plus nivolumab granted FDA approval for first-line treatment of advanced kidney cancer
The Food and Drug Administration (FDA) in the United States has [...]
CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival
The US Food and Drug Administration (FDA) has granted the [...]
Cabozantinib plus atezolizumab for non-clear cell kidney cancer
In this video interview, Dr Monty Pal from the City [...]
Cabozantinib plus atezolizumab combination for advanced kidney cancer
In this study, two doses of cabozantinib were tested in [...]
Immune-related adverse events from cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer
The COSMIC-021 clinical trial investigated a combination of cabozantinib and [...]
Cabozantinib plus atezolizumab for non-clear cell renal cell carcinoma
In this video interview with Dr Monty Pal from the [...]
Sarcopenia is prevalent in kidney cancer patients treated with cabozantinib
Sarcopenia is the loss of muscle mass along with reduced [...]
